Joshua Ziel

A scientist by training, Dr Ziel has spent his career working within and around Pharma and Biotech on some of the most consequential products and product candidates in hematology-oncology, rare disease, and respiratory. He brings a unique blend of strategic insight and operational expertise gleaned from working across the product development lifecycle, from early clinical development to commercialization. Currently the CEO of Bryn Pharma, Dr. Ziel leads Bryn’s team of development and commercialization experts towards completion of the regulatory pathway for NDS1C, a potentially best-in-class intranasal epinephrine treatment for anaphylaxis. Prior to Bryn, Joshua was the COO of Aerami Therapeutics, where he oversaw multiple aspects or corporate and pipeline development, including R&D leadership for inhalation drug-device combination product candidates in cardiopulmonary disease.